Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | HOPE for sickle cell: promising data for voxelotor

Jo Howard • 14 Jun 2019
EHA 2019
Non-Malignant Sickle Cell Disease Voxelotor
HOPE

Jo Howard from Guy’s and St Thomas’ NHS Foundation Trust, London, UK, presents the results from the randomized, placebo-controlled, Phase III Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization (HOPE; NCT03036813) trial of voxelotor in adults and adolescents with sickle cell disease. The data show a significant improvement in anemia and hemolysis in this patient group, indicating that voxelotor has the potential to prevent chronic organ damage. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals